A lot can be achieved therapeutically nowadays

Results of recent studies indicate that greater vitiligo involvement, particularly in visible areas such as the head and arms, is associated with a lower quality of life. The fact that ruxolitinib cream is effective and safe for non-segmental vitiligo – even when affecting the face – has now also been proven in a real-world setting. There are also new data on the combined use of ruxolitinib and phototherapy (NB-UVB). Research is also focusing on new drug candidates, including afamelanotide and bimatoprost.